Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%

All‐cause mortality · paediatric patients following heart surgery

Prophylactic levosimendan showed no clear difference in mortality compared with standard treatment (low certainty).

1 finding from 1 review

All‐cause long‐term mortality · adults with cardiogenic shock

The review found no eligible studies for this question.

1 finding from 1 review

All‐cause short‐term mortality: 1 month · adults with cardiogenic shock or low cardiac output syndrome

The review found no eligible studies for this question.

1 finding from 1 review

All‐cause short‐term mortality: 30 days · adults with cardiogenic shock

It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).

1 finding from 1 review

All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome

It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).

1 finding from 1 review

All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).

1 finding from 1 review

All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).

1 finding from 1 review